300199 翰宇药业
已收盘 08-23 15:00:00
资讯
新帖
简况
翰宇药业(300199)2024年中报简析:亏损收窄,短期债务压力上升
证券之星 · 06:11
翰宇药业(300199)2024年中报简析:亏损收窄,短期债务压力上升
翰宇药业(300199)6月30日股东户数6.26万户,较上期减少13.24%
证券之星 · 08-24 17:04
翰宇药业(300199)6月30日股东户数6.26万户,较上期减少13.24%
翰宇药业(300199.SZ)发布上半年业绩,净亏损1035.88万元,亏损缩窄
智通财经 · 08-23 21:35
翰宇药业(300199.SZ)发布上半年业绩,净亏损1035.88万元,亏损缩窄
翰宇药业新提交1件商标注册申请
证券之星 · 08-20
翰宇药业新提交1件商标注册申请
翰宇药业(300199)8月13日主力资金净卖出1617.53万元
证券之星 · 08-14
翰宇药业(300199)8月13日主力资金净卖出1617.53万元
翰宇药业(300199)8月9日主力资金净卖出911.70万元
证券之星 · 08-12
翰宇药业(300199)8月9日主力资金净卖出911.70万元
09:25 三大指数集体低开,沪指低开0.66%,深成指低开0.86%,创业板指低开0.97% 09:33 医药医疗股开盘拉升,河化股份4连板,新里程涨停,百花医药、舒泰神、振东制药、益方生物、翰宇药业等纷纷跟涨 09:46 深成指、创业板指拉升翻红,医药医疗、教育、船舶制造等方向涨幅居前,沪深京三市上涨个股近2100只 09:54 卫星通信、商业航天概念股再度拉升,航天晨光6连板,中国卫星、中天火箭、延华智能涨停,航天科技、腾达科技等跟涨 10:01 低空经济概念股持续活跃,宗申动力3连板,上工申贝、安达维尔、商络电子、万丰奥威、王子新材等涨超5% 10:07 腾达科技再度涨停,走出10连板,成交额超6亿元,换手超43%,此前4月份的莱绅通灵、华生科技均止步9连板,未能触及10连板,3月份的艾艾精工及2月的克莱机电最高13连板 10:35 CPO概念股震荡走低,新易盛、天孚通信、中际旭创跌超7%,长电科技、景旺电子、罗博特科等跌幅居前 11:11 房地产板块异动拉升,深物业A涨停,大名城、深振业A、我爱我家、沙河股份、津投城开等纷纷走强 11:25 启明信息拉升封涨停,上演地天板走势,日内成交额近23亿元,换手率近24%,该股早盘一度触及跌停
华尔街见闻 · 08-02
09:25 三大指数集体低开,沪指低开0.66%,深成指低开0.86%,创业板指低开0.97% 09:33 医药医疗股开盘拉升,河化股份4连板,新里程涨停,百花医药、舒泰神、振东制药、益方生物、翰宇药业等纷纷跟涨 09:46 深成指、创业板指拉升翻红,医药医疗、教育、船舶制造等方向涨幅居前,沪深京三市上涨个股近2100只 09:54 卫星通信、商业航天概念股再度拉升,航天晨光6连板,中国卫星、中天火箭、延华智能涨停,航天科技、腾达科技等跟涨 10:01 低空经济概念股持续活跃,宗申动力3连板,上工申贝、安达维尔、商络电子、万丰奥威、王子新材等涨超5% 10:07 腾达科技再度涨停,走出10连板,成交额超6亿元,换手超43%,此前4月份的莱绅通灵、华生科技均止步9连板,未能触及10连板,3月份的艾艾精工及2月的克莱机电最高13连板 10:35 CPO概念股震荡走低,新易盛、天孚通信、中际旭创跌超7%,长电科技、景旺电子、罗博特科等跌幅居前 11:11 房地产板块异动拉升,深物业A涨停,大名城、深振业A、我爱我家、沙河股份、津投城开等纷纷走强 11:25 启明信息拉升封涨停,上演地天板走势,日内成交额近23亿元,换手率近24%,该股早盘一度触及跌停
医药医疗股开盘拉升,河化股份4连板,新里程涨停,百花医药、舒泰神、振东制药、益方生物、翰宇药业等纷纷跟涨。
华尔街见闻 · 08-02
医药医疗股开盘拉升,河化股份4连板,新里程涨停,百花医药、舒泰神、振东制药、益方生物、翰宇药业等纷纷跟涨。
翰宇药业(300199)7月24日主力资金净卖出3826.94万元
证券之星 · 07-25
翰宇药业(300199)7月24日主力资金净卖出3826.94万元
最高减重20%!礼来“替尔泊肽”在华获批,效果强过司美格鲁肽?
格隆汇 · 07-22
最高减重20%!礼来“替尔泊肽”在华获批,效果强过司美格鲁肽?
翰宇药业:控股子公司翰宇大理向地方部门发起延期申请后通过了公安局现场复评检查,最终取得换发《云南省工业大麻加工许可证》。
华尔街见闻 · 07-18
翰宇药业:控股子公司翰宇大理向地方部门发起延期申请后通过了公安局现场复评检查,最终取得换发《云南省工业大麻加工许可证》。
翰宇药业(300199.SZ)子公司通过复评换发工业大麻加工许可证
智通财经 · 07-18
翰宇药业(300199.SZ)子公司通过复评换发工业大麻加工许可证
【翰宇药业(300199.SZ)子公司通过复评换发工业大麻加工许可证】智通财经APP讯,翰宇药业(300199.SZ)发布公告,2022年7月22日,公司控股子公司翰宇生物科技(大理)有限公司(“翰宇大理”)收到云南省大理市公安局核发的《云南省工业大麻加工许可证》(批准号:云南省大理市麻加准字1号),有效期限自2022年7月21日至2024年7月20日。
智通财经 · 07-18
【翰宇药业(300199.SZ)子公司通过复评换发工业大麻加工许可证】智通财经APP讯,翰宇药业(300199.SZ)发布公告,2022年7月22日,公司控股子公司翰宇生物科技(大理)有限公司(“翰宇大理”)收到云南省大理市公安局核发的《云南省工业大麻加工许可证》(批准号:云南省大理市麻加准字1号),有效期限自2022年7月21日至2024年7月20日。
翰宇药业:控股股东、实控人拟向深圳担保集团非交易过户合计2.26%股份翰宇药业公告,公司控股股东、实际控制人曾少贵、曾少强拟分别将其持有的1.
格隆汇 · 07-15
翰宇药业:控股股东、实控人拟向深圳担保集团非交易过户合计2.26%股份翰宇药业公告,公司控股股东、实际控制人曾少贵、曾少强拟分别将其持有的1.
翰宇药业:子公司签订约5889万元GLP-1原料药供应合同翰宇药业公告,全资子公司翰宇药业(武汉)有限公司收到客户DS3 RX LLC的合作协议,其拟向翰宇武汉采购金额约810万美元(约合人民币5889万元(含税))的GLP-1原料药。
格隆汇 · 07-10
翰宇药业:子公司签订约5889万元GLP-1原料药供应合同翰宇药业公告,全资子公司翰宇药业(武汉)有限公司收到客户DS3 RX LLC的合作协议,其拟向翰宇武汉采购金额约810万美元(约合人民币5889万元(含税))的GLP-1原料药。
翰宇药业公告,收到智利国家药品管理局颁发的关于注射用特利加压素的批准证书。本次注射用特利加压素获得智利的上市许可,标志着公司拥有了在南美部分市场的销售该药品的资格。
华尔街见闻 · 07-04
翰宇药业公告,收到智利国家药品管理局颁发的关于注射用特利加压素的批准证书。本次注射用特利加压素获得智利的上市许可,标志着公司拥有了在南美部分市场的销售该药品的资格。
【翰宇药业(300199.SZ):注射用特利加压素获智利批准证书】智通财经APP讯,翰宇药业(300199.SZ)公告,公司收到智利国家药品管理局颁发的关于注射用特利加压素的批准证书。
智通财经 · 07-04
【翰宇药业(300199.SZ):注射用特利加压素获智利批准证书】智通财经APP讯,翰宇药业(300199.SZ)公告,公司收到智利国家药品管理局颁发的关于注射用特利加压素的批准证书。
翰宇药业(300199.SZ):注射用特利加压素获智利批准证书
智通财经 · 07-04
翰宇药业(300199.SZ):注射用特利加压素获智利批准证书
翰宇药业:原董事袁建成犯挪用资金罪 被判处有期徒刑三年六个月翰宇药业公告,公司近日收到广东省深圳市南山区人民法院出具的《刑事裁定书》,公司原董事、高级管理人员袁建成犯挪用资金罪已经广东省深圳市南山区人民法院判决。
格隆汇 · 07-03
翰宇药业:原董事袁建成犯挪用资金罪 被判处有期徒刑三年六个月翰宇药业公告,公司近日收到广东省深圳市南山区人民法院出具的《刑事裁定书》,公司原董事、高级管理人员袁建成犯挪用资金罪已经广东省深圳市南山区人民法院判决。
翰宇药业公告,全资子公司翰宇武汉收到国家药品监督管理局签发的关于鲑降钙素原料药《化学原料药上市申请批准通知书》,鲑降钙素是调节钙代谢,抑制甲状旁腺的激素之一,它能显著地降低高周转性骨病的骨钙丢失。
华尔街见闻 · 07-01
翰宇药业公告,全资子公司翰宇武汉收到国家药品监督管理局签发的关于鲑降钙素原料药《化学原料药上市申请批准通知书》,鲑降钙素是调节钙代谢,抑制甲状旁腺的激素之一,它能显著地降低高周转性骨病的骨钙丢失。
暂无数据
公司概况
公司名称:
深圳翰宇药业股份有限公司
所属行业:
医药制造业
上市日期:
2011-04-07
主营业务:
深圳翰宇药业股份有限公司是一家专业从事多肽药物研发、生产和销售的国家级高新技术企业,主要产品包括多肽制剂药品、多肽原料药、客户定制肽、美容肽、固体制剂药品、医疗器械、多肽护肤品、大健康类产品等多个系列。公司上榜2023年广东制造业企业500强,并获得深圳市“专精特新”企业认定;翰宇武汉公司荣膺黄陂区“优秀先进制造业企业”,再次凸显公司高水准的质量优势。
发行价格:
30.19
{"stockData":{"symbol":"300199","market":"SZ","secType":"STK","nameCN":"翰宇药业","latestPrice":9.06,"timestamp":1724396589000,"preClose":9.01,"halted":0,"volume":7805300,"delay":0,"floatShares":666000000,"shares":883000000,"eps":-0.6189,"marketStatus":"已收盘","marketStatusCode":5,"change":0.05,"latestTime":"08-23 15:00:00","open":9.02,"high":9.1,"low":8.93,"amount":70319600,"amplitude":0.0189,"askPrice":9.07,"askSize":459,"bidPrice":9.06,"bidSize":655,"shortable":0,"etf":0,"ttmEps":-0.6189,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"adjPreClose":9.01,"symbolType":"stock","openAndCloseTimeList":[[1724376600000,1724383800000],[1724389200000,1724396400000]],"highLimit":9.91,"lowLimit":8.11,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":883241336,"pbRate":10.64,"roa":"--","roe":"--","epsLYR":-0.58,"committee":-0.260456,"marketValue":8002000000,"floatMarketCap":6034000000,"peRate":-14.638875,"changeRate":0.0055,"turnoverRate":0.0117,"status":0},"requestUrl":"/m/hq/s/300199/tweets","defaultTab":"tweets","newsList":[{"id":"2462693785","title":"翰宇药业(300199)2024年中报简析:亏损收窄,短期债务压力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2462693785","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462693785?lang=zh_cn&edition=full","pubTime":"2024-08-25 06:11","pubTimestamp":1724537517,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期翰宇药业发布2024年中报。截至本报告期末,公司营业总收入2.56亿元,同比下降21.38%,归母净利润-1035.88万元,同比上升69.65%。按单季度数据看,第二季度营业总收入1.05亿元,同比下降29.25%,第二季度归母净利润374.32万元,同比上升107.1%。本报告期翰宇药业短期债务压力上升,流动比率达0.42。本次财报公布的各项数据指标表现一般。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082500000809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300199","BK0070","BK0028","BK0077","BK0188"],"gpt_icon":0},{"id":"2461682257","title":"翰宇药业(300199)6月30日股东户数6.26万户,较上期减少13.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461682257","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461682257?lang=zh_cn&edition=full","pubTime":"2024-08-24 17:04","pubTimestamp":1724490263,"startTime":"0","endTime":"0","summary":"证券之星消息,近日翰宇药业披露,截至2024年6月30日公司股东户数为6.26万户,较3月31日减少9556.0户,减幅为13.24%。在化学制药行业个股中,翰宇药业股东户数高于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.23万户。从股价来看,2024年3月31日至2024年6月30日,翰宇药业区间跌幅为10.85%,在此期间股东户数减少9556.0户,减幅为13.24%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082400009715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0239","BK0070","BK0028","BK0188","BK0077"],"gpt_icon":0},{"id":"2461594134","title":"翰宇药业(300199.SZ)发布上半年业绩,净亏损1035.88万元,亏损缩窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2461594134","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461594134?lang=zh_cn&edition=full","pubTime":"2024-08-23 21:35","pubTimestamp":1724420134,"startTime":"0","endTime":"0","summary":"智通财经APP讯,翰宇药业(300199.SZ)发布2024年半年度报告,公司营业收入2.56亿元,同比下降21.38%;归属于上市公司股东的净亏损1035.88万元,亏损缩窄;归属于上市公司股东的扣除非经常性损益的净亏损5972.38万元,亏损缩窄;基本每股亏损0.01元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1169923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","BK0077","300199","BK0188","BK0070"],"gpt_icon":0},{"id":"2460049074","title":"翰宇药业新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2460049074","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460049074?lang=zh_cn&edition=full","pubTime":"2024-08-20 13:50","pubTimestamp":1724133041,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日深圳翰宇药业股份有限公司新提交1件商标注册申请。商标申请详情如下:今年以来深圳翰宇药业股份有限公司新申请注册商标13件,截止目前公司共持有注册商标451件,另有121件商标尚在注册申请中。数据来源:企查查以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082000017715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0028","BK0188","300199","BK0077"],"gpt_icon":0},{"id":"2459169761","title":"翰宇药业(300199)8月13日主力资金净卖出1617.53万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459169761","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459169761?lang=zh_cn&edition=full","pubTime":"2024-08-14 09:22","pubTimestamp":1723598549,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月13日收盘,翰宇药业报收于9.78元,下跌3.07%,换手率3.68%,成交量24.53万手,成交额2.39亿元。近5日资金流向一览见下表:翰宇药业融资融券信息显示,融资方面,当日融资买入1377.59万元,融资偿还1185.01万元,融资净买入192.58万元。翰宇药业主营业务:特色原料药、注射剂、客户定制肽、固体制剂、药品组合包装类产品和医疗器械产品六大系列。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081400016506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0028","300199","BK0239","BK0070"],"gpt_icon":0},{"id":"2458038648","title":"翰宇药业(300199)8月9日主力资金净卖出911.70万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458038648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458038648?lang=zh_cn&edition=full","pubTime":"2024-08-12 09:22","pubTimestamp":1723425747,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月9日收盘,翰宇药业报收于9.56元,下跌3.04%,换手率3.18%,成交量21.19万手,成交额2.08亿元。近5日资金流向一览见下表:翰宇药业融资融券信息显示,融资方面,当日融资买入1200.76万元,融资偿还1251.11万元,融资净偿还50.36万元。翰宇药业主营业务:特色原料药、注射剂、客户定制肽、固体制剂、药品组合包装类产品和医疗器械产品六大系列。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081200002633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0239","BK0070","BK0028","BK0188","BK0077"],"gpt_icon":0},{"id":"2456452474","title":"09:25 三大指数集体低开,沪指低开0.66%,深成指低开0.86%,创业板指低开0.97% 09:33 医药医疗股开盘拉升,河化股份4连板,新里程涨停,百花医药、舒泰神、振东制药、益方生物、翰宇药业等纷纷跟涨 09:46 深成指、创业板指拉升翻红,医药医疗、教育、船舶制造等方向涨幅居前,沪深京三市上涨个股近2100只 09:54 卫星通信、商业航天概念股再度拉升,航天晨光6连板,中国卫星、中天火箭、延华智能涨停,航天科技、腾达科技等跟涨 10:01 低空经济概念股持续活跃,宗申动力3连板,上工申贝、安达维尔、商络电子、万丰奥威、王子新材等涨超5% 10:07 腾达科技再度涨停,走出10连板,成交额超6亿元,换手超43%,此前4月份的莱绅通灵、华生科技均止步9连板,未能触及10连板,3月份的艾艾精工及2月的克莱机电最高13连板 10:35 CPO概念股震荡走低,新易盛、天孚通信、中际旭创跌超7%,长电科技、景旺电子、罗博特科等跌幅居前 11:11 房地产板块异动拉升,深物业A涨停,大名城、深振业A、我爱我家、沙河股份、津投城开等纷纷走强 11:25 启明信息拉升封涨停,上演地天板走势,日内成交额近23亿元,换手率近24%,该股早盘一度触及跌停","url":"https://stock-news.laohu8.com/highlight/detail?id=2456452474","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456452474?lang=zh_cn&edition=full","pubTime":"2024-08-02 11:42","pubTimestamp":1722570153,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["000953","300158","603228","002178","000011","001379","600584","BK0058","300502","09979","603580","300204","001696","688382","BK0100","300719","399001","SGXZ49509284.SGD","002085","BK0057","600501","09939","000560","002219","600094","000006","002735","003009","300975","600118","399006","605180","BK0050","600322","600843","399300","300199","300757","159938","BK0221","159982","159891","603900","300308","300394","BK0102","002232","000901","600721","000014"],"gpt_icon":0},{"id":"2456341618","title":"医药医疗股开盘拉升,河化股份4连板,新里程涨停,百花医药、舒泰神、振东制药、益方生物、翰宇药业等纷纷跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2456341618","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456341618?lang=zh_cn&edition=full","pubTime":"2024-08-02 09:33","pubTimestamp":1722562381,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["BK0239","159938","BK0077","002219","BK0004","BK0046","BK0066","BK0028","BK0060","600721","300199","BK0216","BK1574","BK0096","BK0102","000953","BK0071","159891","688382","BK0010","BK1161","09939","BK0070","300204","BK0186","BK0236","BK0188","300158","BK1515"],"gpt_icon":0},{"id":"2454830864","title":"翰宇药业(300199)7月24日主力资金净卖出3826.94万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2454830864","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454830864?lang=zh_cn&edition=full","pubTime":"2024-07-25 09:20","pubTimestamp":1721870438,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月24日收盘,翰宇药业报收于9.08元,下跌4.52%,换手率2.93%,成交量19.5万手,成交额1.8亿元。近5日资金流向一览见下表:翰宇药业融资融券信息显示,融资方面,当日融资买入647.72万元,融资偿还2133.5万元,融资净偿还1485.78万元。翰宇药业主营业务:特色原料药、注射剂、客户定制肽、固体制剂、药品组合包装类产品和医疗器械产品六大系列。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072500014740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0028","BK0239","BK0077","300199","BK0188"],"gpt_icon":0},{"id":"2453786850","title":"最高减重20%!礼来“替尔泊肽”在华获批,效果强过司美格鲁肽?","url":"https://stock-news.laohu8.com/highlight/detail?id=2453786850","media":"格隆汇","labels":["Product Release","Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453786850?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:20","pubTimestamp":1721614814,"startTime":"0","endTime":"0","summary":"竞争白热化?","market":"sg","thumbnail":"https://img3.gelonghui.com/1b662-9eab396d-85aa-4a35-807e-33d8ee710c4d.jpg?guru_height=908&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/1b662-9eab396d-85aa-4a35-807e-33d8ee710c4d.jpg?guru_height=908&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/869192","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU1035775433.USD","LU0094547139.USD","LU0708995401.HKD","LU0109391861.USD","IE0002141913.USD","300199","IE0004445239.USD","GB00BDT5M118.USD","LU1061106388.HKD","LU0061475181.USD","BK4533","LU1804176565.USD","603087","IE00BJJMRZ35.SGD","LU0097036916.USD","LU0122379950.USD","BK0188","LU0079474960.USD","BK4532","BK4516","LU0385154629.USD","LU1551013342.USD","BK4007","LU0256863811.USD","LU0820561909.HKD","IE00BJT1NW94.SGD","LU1093756168.USD","IE00BJLML261.HKD","IE0009355771.USD","LU0882574055.USD","IE00B1BXHZ80.USD","LU1280957306.USD","BK0077","LU0096364046.USD","LU2328871848.SGD","BK0187","LU0114720955.EUR","BK4534","LU0943347566.SGD","LU1093756325.SGD","BK0175","LU0058720904.USD","LU1551013425.SGD","NVO","LI","LU0471298694.HKD","000963","LU1623119135.USD","BK0183","BK0239"],"gpt_icon":1},{"id":"2452917247","title":"翰宇药业:控股子公司翰宇大理向地方部门发起延期申请后通过了公安局现场复评检查,最终取得换发《云南省工业大麻加工许可证》。","url":"https://stock-news.laohu8.com/highlight/detail?id=2452917247","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452917247?lang=zh_cn&edition=full","pubTime":"2024-07-18 16:55","pubTimestamp":1721292925,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["BK0077","BK0028","BK0070","BK0239","BK0188","300199"],"gpt_icon":0},{"id":"2452725151","title":"翰宇药业(300199.SZ)子公司通过复评换发工业大麻加工许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2452725151","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452725151?lang=zh_cn&edition=full","pubTime":"2024-07-18 16:45","pubTimestamp":1721292349,"startTime":"0","endTime":"0","summary":"智通财经APP讯,翰宇药业(300199.SZ)发布公告,2022年7月22日,公司控股子公司翰宇生物科技(大理)有限公司(“翰宇大理”)收到云南省大理市公安局核发的《云南省工业大麻加工许可证》(批准号:云南省大理市麻加准字1号),有效期限自2022年7月21日至2024年7月20日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","300199","BK0239","BK0188","BK0070","BK0028"],"gpt_icon":0},{"id":"2452172300","title":"【翰宇药业(300199.SZ)子公司通过复评换发工业大麻加工许可证】智通财经APP讯,翰宇药业(300199.SZ)发布公告,2022年7月22日,公司控股子公司翰宇生物科技(大理)有限公司(“翰宇大理”)收到云南省大理市公安局核发的《云南省工业大麻加工许可证》(批准号:云南省大理市麻加准字1号),有效期限自2022年7月21日至2024年7月20日。","url":"https://stock-news.laohu8.com/highlight/detail?id=2452172300","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452172300?lang=zh_cn&edition=full","pubTime":"2024-07-18 16:45","pubTimestamp":1721292349,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0028","BK0239","BK0077","300199","BK0188","159837","BK0070"],"gpt_icon":0},{"id":"2451970642","title":"翰宇药业:控股股东、实控人拟向深圳担保集团非交易过户合计2.26%股份翰宇药业公告,公司控股股东、实际控制人曾少贵、曾少强拟分别将其持有的1.","url":"https://stock-news.laohu8.com/highlight/detail?id=2451970642","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451970642?lang=zh_cn&edition=full","pubTime":"2024-07-15 21:00","pubTimestamp":1721048419,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","BK0188","BK0070","BK0077","BK0239","300199"],"gpt_icon":0},{"id":"2450898726","title":"翰宇药业:子公司签订约5889万元GLP-1原料药供应合同翰宇药业公告,全资子公司翰宇药业(武汉)有限公司收到客户DS3 RX LLC的合作协议,其拟向翰宇武汉采购金额约810万美元(约合人民币5889万元(含税))的GLP-1原料药。","url":"https://stock-news.laohu8.com/highlight/detail?id=2450898726","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450898726?lang=zh_cn&edition=full","pubTime":"2024-07-10 19:16","pubTimestamp":1720610207,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["300199","BK0188","BK4144","BK4590","BK4139","BK0028","BK0239","BK0077","BK0070","GLP","VIRI"],"gpt_icon":0},{"id":"2448142674","title":"翰宇药业公告,收到智利国家药品管理局颁发的关于注射用特利加压素的批准证书。本次注射用特利加压素获得智利的上市许可,标志着公司拥有了在南美部分市场的销售该药品的资格。","url":"https://stock-news.laohu8.com/highlight/detail?id=2448142674","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448142674?lang=zh_cn&edition=full","pubTime":"2024-07-04 16:41","pubTimestamp":1720082466,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["300199","BK0188","BK0077","BK0239","BK0070","BK0028"],"gpt_icon":0},{"id":"2448414982","title":"【翰宇药业(300199.SZ):注射用特利加压素获智利批准证书】智通财经APP讯,翰宇药业(300199.SZ)公告,公司收到智利国家药品管理局颁发的关于注射用特利加压素的批准证书。","url":"https://stock-news.laohu8.com/highlight/detail?id=2448414982","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448414982?lang=zh_cn&edition=full","pubTime":"2024-07-04 16:30","pubTimestamp":1720081810,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0188","BK0077","BK0028","300199","BK0239","BK0070"],"gpt_icon":0},{"id":"2448414501","title":"翰宇药业(300199.SZ):注射用特利加压素获智利批准证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2448414501","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448414501?lang=zh_cn&edition=full","pubTime":"2024-07-04 16:30","pubTimestamp":1720081810,"startTime":"0","endTime":"0","summary":"智通财经APP讯,翰宇药业(300199.SZ)公告,公司收到智利国家药品管理局颁发的关于注射用特利加压素的批准证书。注射用特利加压素的适应症为:治疗食管静脉曲张出血。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0188","BK0070","BK0239","300199","BK0077"],"gpt_icon":0},{"id":"2448772831","title":"翰宇药业:原董事袁建成犯挪用资金罪 被判处有期徒刑三年六个月翰宇药业公告,公司近日收到广东省深圳市南山区人民法院出具的《刑事裁定书》,公司原董事、高级管理人员袁建成犯挪用资金罪已经广东省深圳市南山区人民法院判决。","url":"https://stock-news.laohu8.com/highlight/detail?id=2448772831","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448772831?lang=zh_cn&edition=full","pubTime":"2024-07-03 18:09","pubTimestamp":1720001388,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0070","BK0188","BK0077","BK0239","300199","BK0028"],"gpt_icon":0},{"id":"2448965524","title":"翰宇药业公告,全资子公司翰宇武汉收到国家药品监督管理局签发的关于鲑降钙素原料药《化学原料药上市申请批准通知书》,鲑降钙素是调节钙代谢,抑制甲状旁腺的激素之一,它能显著地降低高周转性骨病的骨钙丢失。","url":"https://stock-news.laohu8.com/highlight/detail?id=2448965524","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448965524?lang=zh_cn&edition=full","pubTime":"2024-07-01 16:31","pubTimestamp":1719822688,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["BK0070","BK0028","BK0188","BK0077","300199","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2011-04-07","address":"广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼","stockEarnings":[{"period":"1week","weight":-0.0592},{"period":"1month","weight":-0.0022},{"period":"3month","weight":-0.238},{"period":"6month","weight":-0.3234},{"period":"1year","weight":-0.0163},{"period":"ytd","weight":-0.3328}],"companyName":"深圳翰宇药业股份有限公司","boardCode":"AI0027","perCapita":"11283股","boardName":"医药制造业","registeredCapital":"88324万元","compareEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":-0.0164},{"period":"3month","weight":-0.0759},{"period":"6month","weight":-0.0501},{"period":"1year","weight":-0.0739},{"period":"ytd","weight":-0.0405}],"survey":" 深圳翰宇药业股份有限公司是一家专业从事多肽药物研发、生产和销售的国家级高新技术企业,主要产品包括多肽制剂药品、多肽原料药、客户定制肽、美容肽、固体制剂药品、医疗器械、多肽护肤品、大健康类产品等多个系列。公司上榜2023年广东制造业企业500强,并获得深圳市“专精特新”企业认定;翰宇武汉公司荣膺黄陂区“优秀先进制造业企业”,再次凸显公司高水准的质量优势。","serverTime":1724561174261,"listedPrice":30.19,"stockholders":"62595人(较上一季度减少13.24%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰宇药业,300199,翰宇药业股票,翰宇药业股票老虎,翰宇药业股票老虎国际,翰宇药业行情,翰宇药业股票行情,翰宇药业股价,翰宇药业股市,翰宇药业股票价格,翰宇药业股票交易,翰宇药业股票购买,翰宇药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}